A Phase 1b/2a Study of DISC-0974 in People With Myelofibrosis and Anemia


Full Title

A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia


Researchers want to find the highest dose of DISC-0974 to use in people with myelofibrosis and anemia. Myelofibrosis happens when bone marrow cells called fibroblasts make too much fibrous (scar) tissue. The bone marrow is not able to make enough blood cells, which leads to anemia. Anemia is a reduced number of red blood cells, and it causes tiredness and shortness of breath.

DISC-0974 helps lower levels of a hormone called hepcidin, which controls iron levels. People with myelofibrosis often have high hepcidin levels and low iron levels, leading to anemia. By lowering hepcidin levels, DISC-0974 may treat your anemia. DISC-0974 is given as a subcutaneous (under the skin) injection.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have myelofibrosis with anemia.
  • Have been on a stable dose or completed prior myelofibrosis treatments at least 4 weeks before getting DISC-0974.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Prioty Islam’s office at 646-608-4273.




Phase I/II (phases 1 and 2 combined)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID